Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||PRS-343 + Tucatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PRS-343||HER2 (ERBB2) Antibody 57 TNFRSF9 Antibody 15||PRS-343 is a bispecific antibody targeting both CD137 (4-1BB) and Erbb2 (Her2), resulting in enhanced anti-tumor immune response against Erbb2 (Her2)-positive tumor cells (Eur J Cancer, Dec 2016, 69 (Suppl. 1): S99, abstract 301, PMID: 31138587).|
|Tucatinib||Tukysa||ONT-380|ARRY-380|irbinitinib||HER2 Inhibitor 31||Tukysa (tucatinib) selectivity inhibits ERBB2 (HER2), resulting in decreased proliferation and increased apoptosis in ERBB2 (HER2) expressing tumor cells (PMID: 28053022). Tukysa (tucatinib) in combination with Herceptin (trastuzumab) and Xeloda (capecitabine) is FDA approved for use in patients with advanced unresectable or metastatic ERBB2 (HER2)-positive breast cancer, including patients with brain metastasis, who have received prior anti-HER2 therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05190445||Phase II||PRS-343 + Tucatinib Paclitaxel + PRS-343 + Ramucirumab||Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma||Recruiting||USA||0|